Список литературы

1. Pal T., Permuth-Wey J., Betts J.A. et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.//Cancer - 2005. - V. 104, N 12. - P. 2807 - 16.

2. Rooth C. Ovarian cancer: risk factors, treatment and management. //Br J Nurs. - 2013. - V. 22, N 17. - P. S23 - 30.

3. Злокачественные новообразования в России в 2015 году (заболеваемость и смертность)/под редакцией Каприна А.Д., Старинского В.В., Петровой Г.В. - М.: МНИОИ им. П.А. Герцена - филиал ФГБУ "НМИРЦ" Минздрава России, - 2017. - 250 с.

4. Ebell M.H., Culp M.B., Radke T.J. A Systematic Review of Symptoms for the Diagnosis of Ovarian Cancer.//Am J Prev Med. - 2016. - V. 50, N 3. - P. 384 - 94.

5. NCCN guidelines panel. Epithelial Ovarian Cancer (including Fallopian Tube Cancer and Primary Peritoneal Cancer). Version 1.2016.//published online: https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#ovarian. 2016. P. OV1. (https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#ovarian)

6. Stiekema A., Boldingh Q.J., Korse C.M. et al. Serum human epididymal protein 4 (HE4) as biomarker for the differentiation between epithelial ovarian cancer and ovarian metastases of gastrointestinal origin.//Gynecol Oncol. - 2015. - V. 136, N 3. - P. 562 - 6. (https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#ovarian)

7. Santotoribio J.D., Garcia-de la Torre A., Canavate-Solano C. et al. Cancer antigens 19.9 and 125 as tumor markers in patients with mucinous ovarian tumors.//Eur J Gynaecol Oncol. - 2016. - V. 37, N 1. - P. 26 - 9. (https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#ovarian)

8. Colombo N., Peiretti M., Garbi A. et al. Non-Epithelial Ovarian Cancer: ESMO Clinical Practice Guidelines. //Ann Oncol. - 2012. V. 23 (Suppl 7). - P. vii20 - vii26. (https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#ovarian)

9. Ledermann J.A., Raja F.A., Fotopoulou C. et al. Newly Diagnosed and Relapsed Epithelial Ovarian Carcinoma: ESMO Clinical Practice Guidelines.//Ann Oncol. - 2013. - V. 24 (Suppl 6). - P. vi24 - vi32. (https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#ovarian)

10. Sankaranarayanan R. Screening for cancer in low- and middle-income countries. //Ann Glob Health. - 2014. - V. 80, N 5. - P. 412 - 7 (https://www.nccn.Org/professionals/physician_gls/f_guidelines.asp#ovarian)

11. Yadav B.S., Sharma S.C., Robin T.P. Synchronous primary carcinoma of breast and ovary versus ovarian metastases.//Semin Oncol. - 2015. - V. 42, N 2. - P. e13 - 24. (https://www.nccn.Org/professionals/physician_gls/f_guidelines.asp#ovarian)

12. Stuart G., Kitchener H., Bacon M. et al. 2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer Int J Gynecol Cancer 2011; 21: 750Y755 (https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#ovarian)

13. Trimbos J.B., Parmar M., Vergote I. et al. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst. 2003 Jan 15; 95(2): 105 - 12. (https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#ovarian)

14. Vergote I., Trope C.G., Amant F. et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.//N Engl J Med. - 2010. - V. 363. - P. 943 - 53. (https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#ovarian)

15. Young R.C., Walton L.A., Ellenberg S.S. et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer.//N Engl J Med. - 1990. - V. 322. - P. 1021 - 7. (https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#ovarian)

16. Young R.C., Brady M.F., Nieberg R.M. et al. Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin - A Gynecologic Oncology Group study.//J Clin Oncol 2003. V 21, N 23. P. 4350 - 5. (https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#ovarian)

17. Bolis G., Colombo N., Pecorelli S. et al. Adjuvant treatment for early epithelial ovarian cancer: results of two randomized clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). GICOG: Gruppo Interregionale Collaborativo in Ginecologia Oncologica.//Ann Oncol. - 1995. - V. 6, N 9. - P. 887 - 93 (https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#ovarian)

18. Oza A.M., Cook A.D., Pfisterer J. et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.//The Lancet Oncology. 2015. - V. 16, N 8. - P. 928 - 936. (https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#ovarian)

19. Gershenson D., Bodurka D., Coleman R. et al. Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum//J Clin Oncol. - 2017. In print (https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#ovarian)

20. Rustin G.J., Vergote.I, Eisenhauer E. et al. Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG)//Int J Gynecol Cancer. - 2011. V 21, N 2. P. 419 - 23. (https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#ovarian)

21. Harter P., du Bois A., Hahmann M. et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. //Ann Surg Oncol. - 2006. - V. 13, N 12. - P. 1702 - 10. (https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#ovarian)

22. Harter P., Sehouli J., Reuss A. et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO.//Int J Gynecol Cancer. - 2011. - V. 21, N 2. - P. 289 - 95. (https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#ovarian)

23. Rustin G.J., van der Burg M.E., Griffin C.L. et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial.//Lancet. - 2010. V. 376, N 9747. - P. 1155 - 63 (https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#ovarian)

24. Markman M, Rothman R, Hakes T, et al: Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9: 389 - 393, 1991 (https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#ovarian)

25. Gore M, Fryatt I, Wiltshaw E, Dawson T: Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these components. Gynecol Oncol 36: 207 - 211, 1990 (https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#ovarian)

26. Mahner S., Meier W., du Bois A. et al. Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial. Eur J Cancer. 2015 Feb; 51(3): 352 - 8 (https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#ovarian)

27. The ICON and AGO Collaborators Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial//Lancet. - 2003. - V. 361. - P. 2099 - 106 (https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#ovarian)

28. Hoskins P.J., Le N. Identifying patients unlikely to benefit from further chemotherapy: A descriptive study of outcome at each relapse in ovarian cancer//Gynecologic Oncology. 2005. - V. 97. - P. 862 - 869 (https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#ovarian)

29. Aghajanian C, Goff B, Nycum LR et al. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer.//Gynecol Oncol. - 2015. - V. 139, N 1. - P. 10 - 6. (https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#ovarian)

30. Pujade-Lauraine E., Hilpert F. Weber B. et al. Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial//J Clin Oncol. - 2014. - V. 32. - P. 4014 - 4025 (https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#ovarian)

31. Okamoto A., Sugiyama T., Hamano T. et al. Randomized phase III trial of paclitaxel/carboplatin (PC) versus cisplatin/irinotecan (CPT-P) as first-line chemotherapy in patients with clear cell carcinoma (CCC) of the ovary: A Japanese Gynecologic Oncology Group (JGOG)/GCIG study.//J Clin Oncol - 2014. - V. 32, N 5s (suppl; abstr 5507) (https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#ovarian)

32. Sato S, Itamochi H, Kigawa J, Oishi T, Shimada M, Sato S, Naniwa J, Uegaki K, Nonaka M, Terakawa N. Combination chemotherapy of oxaliplatin and 5-fluorouracil may be an effective regimen for mucinous adenocarcinoma of the ovary: a potential treatment strategy.//Cancer Sci. - 2009. - V. 100, N 3. - P. 546 - 51. (https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#ovarian)

33. Ledermann J., Harter P., Gourley C. et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014 Jul; 15(8): 852 - 61. (https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#ovarian)

34. Swenerton K.D., Santos J.L., Gilks C.B. et al. Histotype predicts the curative potential of radiotherapy: the example of ovarian cancers//Annals of Oncology. 2011. V. 22. - P. 341 - 347. (https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#ovarian)

35. Holt K.A., Mogensen O., Jensen P.T., Hansen D.G. Goal setting in cancer rehabilitation and relation to quality of life among women with gynaecological cancer. //(https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#ovarian) Acta Oncol. - 2015. - V. 54, N 10. - P. 1814 - 23. (https://www.ncbi.nlm.nih.gov/pubmed/25943136)